ALKERMES PHARMA IRELAND LIMITED

Alkermes Pharma Ireland Limited is a life-sciences company that leverages deep neuroscience expertise to develop medicines for complex psychiatric and neurological disorders. With a focus on real-world impact, the firm advances a pipeline of investigational candidates, including Alixorexton - an oral orexin-2 receptor agonist now in phase 2 trials for narcolepsy type 1, type 2 and idiopathic hypersomnia - and a paediatric formulation of olanzapine and samidorphan, currently in phase 3 for schizophrenia and bipolar I disorder. Early-stage programmes such as ALKS 4510 and ALKS 7290 explore novel orexin-2 receptor mechanisms across central-nervous-system indications.

The company's commitment to scientific rigour and compassionate care is reflected in recent milestones, such as Alixorexton receiving breakthrough-therapy designation from the U.S. FDA and Alkermes presenting at the 44th Annual J.P. Morgan Healthcare Conference. By combining cutting-edge research with a patient-centred ethos, Alkermes Pharma Ireland strives to bring meaningful therapeutic options to people living with serious, hard-to-treat conditions.